Invesaro

Stocks Health care QDEL

NASDAQ · Health care

QuidelOrtho Corp (QDEL)

QuidelOrtho Corp brought in $2.7B of revenue over the twelve months to June 28, 2026, down 2.5% from a year earlier. It posted a net loss of $1B. In fiscal 2025 capital spending exceeded operating cash flow by $83M. At June 28, 2026 it held $123.4M in cash against $2.9B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.

Revenue (last 12 months)
$2.7B
-2.5% year on year
Net margin
-39.2%

What QuidelOrtho Corp does

QuidelOrtho Corp is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker QDEL.

Revenue and profit by year

Revenue
FY20: $1.7B $1.7B FY20FY22: $1.7B $1.7B FY22FY22: $3.3B $3.3B FY22FY23: $3B $3B FY23FY24: $2.8B $2.8B FY24FY25: $2.7B $2.7B FY25
Net income
FY20: $810.3M $810.3M FY20FY22: $704.2M $704.2M FY22FY22: $548.7M $548.7M FY22FY23: -$10.1M -$10.1M FY23FY24: -$2.1B -$2.1B FY24FY25: -$1.1B -$1.1B FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$2.7B-$919.2M-$1.1B-$16.69-$83M
2024$2.8B-$2B-$2.1B-$30.54-$112.1M
2023$3B$139.1M-$10.1M-$0.15$70.9M
2022$3.3B$843.7M$548.7M$9.56$744.4M
2022$1.7B$906M$704.2M$16.43$513.1M
2020$1.7B$1.1B$810.3M$18.60$564.8M

Latest SEC filings

What QuidelOrtho Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 23, 2026
    Material agreement 8-K
  2. August 14, 2026
    Passive stake changed SCHEDULE 13G/A
  3. August 14, 2026
    Passive stake changed SCHEDULE 13G/A
  4. August 7, 2026
    Quarterly report 10-Q · period to June 28, 2026
  5. August 6, 2026
    Quarterly results 8-K
  6. August 5, 2026
    Passive stake changed SCHEDULE 13G/A
  7. July 13, 2026
    Employee stock plan registration S-8
  8. July 8, 2026
    Passive stake (5% or more) SCHEDULE 13G
  9. June 23, 2026
    Executive or director change 8-K
  10. June 16, 2026
    Shareholder vote results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 17, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about QDEL

What does QuidelOrtho Corp do?

QuidelOrtho Corp is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker QDEL.

Is QuidelOrtho Corp profitable?

No. Over the twelve months to June 28, 2026 it reported a net loss of $1B on revenue of $2.7B.

How much revenue does QuidelOrtho Corp make?

Over the twelve months to June 28, 2026 QuidelOrtho Corp reported revenue of $2.7B. That is 2.5% less than a year earlier.

When did QuidelOrtho Corp last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 28, 2026. Its newest filing of any kind is the material agreement from September 23, 2026.

Similar companies

IDXX
Idexx Laboratories Inc
LNTH
Lantheus Holdings, Inc.
NEOG
Neogen Corp
MYGN
Myriad Genetics Inc
NTLA
Intellia Therapeutics, Inc.
TKNO
Alpha Teknova, Inc.

Follow QDEL

Get an email when QuidelOrtho Corp files with the SEC: results, executive changes, material agreements and annual reports.

Follow QDEL: get an email when it files

Where the numbers come from

Financial figures are the values QuidelOrtho Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.